[613] | 1 | DVBCWSM1 ;ALB/CMM RESPIRATORY, MISC. DISEASES WKS TEXT - 1 ;7 Oct 2000
|
---|
| 2 | ;;2.7;AMIE;**34**;Apr 10, 1995
|
---|
| 3 | ;
|
---|
| 4 | ;
|
---|
| 5 | TXT ;
|
---|
| 6 | ;;A. Review of Medical Records:
|
---|
| 7 | ;;
|
---|
| 8 | ;;B. Medical History (Subjective Complaints):
|
---|
| 9 | ;; Comment on:
|
---|
| 10 | ;;
|
---|
| 11 | ;; 1. Fever and/or night sweats.
|
---|
| 12 | ;; 2. Weight loss or gain.
|
---|
| 13 | ;; 3. Daytime hypersomnolence.
|
---|
| 14 | ;; 4. Hemoptysis.
|
---|
| 15 | ;; 5. Describe current treatment such as anticoagulant, tracheostomy, CPAP,
|
---|
| 16 | ;; oxygen, or antimicrobial therapy.
|
---|
| 17 | ;; 6. If malignant disease, state initial treatment date, site of original
|
---|
| 18 | ;; tumor, type of tumor, types of treatment used, and date treatment is
|
---|
| 19 | ;; expected to end. If treatment has been completed, state date treatment
|
---|
| 20 | ;; was completed.
|
---|
| 21 | ;;
|
---|
| 22 | ;;C. Physical Examination (Objective Findings):
|
---|
| 23 | ;; Address each of the following as appropriate to the condition being
|
---|
| 24 | ;; examined and fully describe current findings:
|
---|
| 25 | ;;
|
---|
| 26 | ;; 1. Pulmonary Hypertension, RVH, cor pulmonale, or congestive heart failure.
|
---|
| 27 | ;; 2. Residuals of pulmonary embolism.
|
---|
| 28 | ;; 3. Respiratory Failure.
|
---|
| 29 | ;; 4. Evidence of chronic pulmonary thromboembolism.
|
---|
| 30 | ;; 5. If ankylosing spondylitis, is there restriction of the chest excursion
|
---|
| 31 | ;; and dyspnea on minimal exertion?
|
---|
| 32 | ;; 6. Describe all residuals of malignancy including those due to treatment.
|
---|
| 33 | ;;
|
---|
| 34 | ;;D. Diagnostic and Clinical Tests:
|
---|
| 35 | ;;
|
---|
| 36 | ;;1. Pulmonary Function Tests, if indicated. The FEV-1,FVC, and FEV-1/FVC should
|
---|
| 37 | ;; be included. Both pre- and post-bronchodilatation pulmonary function
|
---|
| 38 | ;; test results should be reported. If post-bronchodilatation testing is not
|
---|
| 39 | ;; conducted in a particular case, please provide an explanation of why not.
|
---|
| 40 | ;; A DLCO may or may not be done routinely as part of pulmonary function
|
---|
| 41 | ;; testing at a particular facility. If there is a disparity between the results
|
---|
| 42 | ;; of different tests, please indicate which tests are more likely to
|
---|
| 43 | ;; accurately reflect the severity of the condition.
|
---|
| 44 | ;;
|
---|
| 45 | ;;TOF
|
---|
| 46 | ;; DLCO note: If the DLCO was not done as a routine part of pulmonary
|
---|
| 47 | ;; function testing, the examiner should use his or her judgment, based on
|
---|
| 48 | ;; the specific condition (e.g., whether it is obstructive, interstitial,
|
---|
| 49 | ;; etc.) and other available information about the condition, as to whether
|
---|
| 50 | ;; a DLCO test is needed. If it may provide useful information about the
|
---|
| 51 | ;; severity of the condition, it should be requested and reviewed before
|
---|
| 52 | ;; the examination report is submitted. If the examiner determines that
|
---|
| 53 | ;; the DLCO test is not needed, a statement as to why not (e.g., there are
|
---|
| 54 | ;; decreased lung volumes that would not yield valid test results) should be
|
---|
| 55 | ;; included in the report. Such a statement could avoid a remand from BVA when
|
---|
| 56 | ;; the test is not done. However, in the case of BVA remand in which DLCO
|
---|
| 57 | ;; is requested, the DLCO MUST be done unless there is a medical
|
---|
| 58 | ;; contraindication.
|
---|
| 59 | ;;
|
---|
| 60 | ;; 2. If sleep apnea is suspected, order Sleep Studies.
|
---|
| 61 | ;; 3. Chest X-ray if necessary to document sarcoidosis or other parenchymal
|
---|
| 62 | ;; disease.
|
---|
| 63 | ;; 4. Include results of all diagnostic and clinical tests conducted in
|
---|
| 64 | ;; the examination report.
|
---|
| 65 | ;;
|
---|
| 66 | ;;E. Diagnosis:
|
---|
| 67 | ;;
|
---|
| 68 | ;;
|
---|
| 69 | ;;Signature: Date:
|
---|
| 70 | ;;END
|
---|